Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat in Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT00303953Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belinostat in B-cell non-Hodgkin lymphoma, sponsored by National Cancer Institute. Started Jan 2006; status: completed.
02
Drugs
belinostat
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00303953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303953.